SCHEMBL23748207

SCHEMBL23748207

CCOC(=O)c1c(OC)cc(F)c(F)c1CBr

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 2/20 0.43
LMNA P02545 5/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.40
CYP3A4 P08684 2/20 0.40
HSD17B2 P37059 1/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748272 0.82 PRKCZ (0.46) PRKCZLMNAL3MBTL1ALDH1A1HPGD
SCHEMBL15729569 0.82 PRKCZ (0.49) PRKCZLMNAL3MBTL1ALDH1A1CYP3A4
SCHEMBL3067123 0.78 PRKCZ (0.45) PRKCZLMNAL3MBTL1ALDH1A1HPGD
SCHEMBL23748199 0.78 MAPT (0.46) PRKCZLMNAL3MBTL1ALDH1A1GAA
SCHEMBL3552780 0.77 CYP4F2 (0.46) LMNAL3MBTL1ALDH1A1GAAMAPT
SCHEMBL31502538 0.74 LMNA (0.47) LMNAL3MBTL1ALDH1A1HSD17B2SMN1; SMN2
SCHEMBL17091203 0.74 LMNA (0.47) LMNAL3MBTL1ALDH1A1HSD17B2SMN1; SMN2
SCHEMBL1999399 0.73 NR1H2 (0.53) ALDH1A1HPGDCYP3A4NR1H2NR1H3
SCHEMBL26437234 0.72 LMNA (0.54) LMNAL3MBTL1ALDH1A1HPGDCYP3A4
SCHEMBL1999063 0.72 NR1H2 (0.52) PRKCZALDH1A1HPGDCYP3A4NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
CN-114057769-A Macrocyclic pyridazine compound and application thereof 上海拓界生物医药科技有限公司 2022-02-18 CN disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-113195502-A Macrocyclic influenza endonuclease inhibitors 詹森生物制药有限公司 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 PRKCZ 1812/4885LMNA 1057/4885L3MBTL1 2124/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP PRKCZ 2236/4885LMNA 965/4885L3MBTL1 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.